nordial Transforming home dialysis

Integrated Care Platform for Home Dialysis

Founded in December 2025, Nordial is developing an **Integrated Care Platform (ICP) to transform home dialysis** while making it more accessible, affordable, personalized and sustainable. Its core innovation, OD1, is a peritoneal dialysis machine designed to prepare pharmaceutical-grade dialysis fluid (dialysate) on demand from purified tap water and concentrates directly at patients' homes. OD1 integrates with the KidneyConnect and PROCare digital ecosystem to support remote monitoring and treatment personalization, while reducing the costs and environmental impact of care.


Challenge

Conventional home peritoneal dialysis depends on bulky prefilled bags, complex daily routines and fragmented follow-up, placing a substantial burden on patients, caregivers and healthcare teams. These constraints limit adoption while increasing storage needs, logistical costs, resource consumption and packaging waste.

>400 kg
bags/ month

20-30 min
session setup

>140 kg
plastic waste / year



Nordial Integrated Care Platform

One connected pathway from Prescription to Treatment at home

OD1 Dialysis Machine	Designed to Generate pharmaceutical-grade dialysate on demand from purified tap water and concentrates. **1 L** concentrate replaces **12 L** of pre-filled dialysate bags
Kidney Connect	Digital control layer designed for machine control, remote monitoring, treatment records, prescription updates and clinical-system integration
PROCare	Captures patient-reported outcomes and experiences to inform clinical follow-up, provide real-time clinical insights and support personalized treatments

Business Model

Hardware
OD1 peritoneal dialysis machine
Sold to hospitals and dialysis providers

Consumables
Recurring revenue from filter cartridges and proprietary concentrates, priced per patient/year

Software
Kidney Connect and PROCare Applications
SaaS licenses and subscriptions

Maintenance & Support
Annual maintenance and service contracts, priced per machine/year

Traction, Partnerships & Intellectual Property

PROCare pilots underway in **France and Senegal.** Dialysate formulation and testing in progress with **GRITA Lab.** Clinical collaborations with **CHU Lille**, **CHU Caen**, **CH du Mans** and **Santélys**.

IP: French patent application filed in June 2025, followed by international PCT application in June 2026; two additional filings in preparation.

Development & Commercialization Roadmap

2026
PoC development; dialysate formulation & quality testing

2027–29
Prototype development; pharmaceutical validation; functional & preclinical testing

2030
Clinical investigations & CE Marking; Commercial launch in France

2031+
International expansion Europe (Belgium, Spain, Germany, Italy) and India

Indicative timeline, subject to clinical outcomes, regulatory approvals and market-access requirements.

Unmet Need

850M
People worldwide affected by chronic kidney disease

14.5M
Projected dialysis population by 2030

<11%
Worldwide dialysis patients are treated at home

Market Oppurtunity

$67B (10.1% CAGR)
Projected home dialysis market by 2035

Revenue

20.5M €
Projected revenue by 2034

Positive cash flow
Expected by 2033

Funding

3M € | 2M € in equity
1M € non-dilutive

Seed Funding Target

Expanding engineering and pharmaceutical capabilities, core quality, regulatory and clinical hires, prototype verification, dialysate process validation, preclinical studies, early clinical investigations, engage Notifed Body

Team & Advisory Board

Chetan Kumar Velumurugan, PhD
Co-founder & CEO
Biomedical Engineer with 10+ years of experience in product engineering and software development

Dr. Victor Fages
Co-founder & CSO
Nephrologist at CHU Lille specializing in peritoneal dialysis, with expertise in clinical research

A **strong scientific and strategic advisory board** spanning nephrology, medical-device innovation, pharmaceutical sciences, business strategy, market access, sustainable healthcare and intellectual property.

Confidential · For Investor use only · No reproduction, distribution or disclosure without NORDIAL's prior written consent.